Celcuity Inc


Celcuity Inc

Health CarePharmaceuticals and Biotechnology
  • Price (USD)10.36
  • Today's Change0.045 / 0.44%
  • Shares traded247.37k
  • 1 Year change+18.21%
  • Beta0.6097
Data delayed at least 15 minutes, as of Mar 30 2023 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Celcuity, Inc. is a clinical-stage biotechnology company. The Company is seeking to extend the lives of cancer patients by pursuing an integrated therapeutic (Rx) and companion diagnostic (CDx) strategy. Its therapeutic efforts are focused on developing molecularly targeted therapies that address the same cancer driver a CELsignia companion diagnostic can identify. The Company's lead therapeutic candidate is gedatolisib, a potent, reversible dual inhibitor that selectively targets all Class I isoforms of PI3K and mammalian target of rapamycin (mTOR). Its mechanism of action and pharmacokinetic properties are highly differentiated from other investigational therapies that target PI3K or mTOR alone or together. Its initial clinical development program for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), HER2-negative, advanced, or metastatic breast cancer. The Company's additional clinical development programs focus on various other tumor types.

  • Revenue in USD (TTM)0.00
  • Net income in USD-40.37m
  • Incorporated2017
  • Employees45.00
  • Location
    Celcuity Inc16305 36th Ave N Ste 100MINNEAPOLIS 55446-4285United StatesUSA
  • Phone+1 (763) 392-0767
  • Fax+1 (302) 655-5049
  • Websitehttp://celcuity.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
PMV Pharmaceuticals Inc0.00-73.32m218.80m62.00--0.8893-----1.61-1.610.005.380.00----0.00-24.36---25.33--------------0.00-------26.75------
Pyxis Oncology Inc0.00-120.72m221.88m75.00--1.31-----3.65-3.650.004.580.00----0.00-49.13---54.74--------------0.00-------58.89------
Petro Usa Inc0.00-19.82k222.03m-----------0.0635-0.06350.00-0.0006---------------------------69.79--------53.07------
Cabaletta Bio Inc0.00-52.98m222.52m58.00--2.00-----1.80-1.800.003.550.00----0.00-43.55-34.04-47.00-35.73------------0.00-------14.44------
Kezar Life Sciences Inc0.00-68.24m223.74m84.00--0.802-----1.01-
Icosavax Inc2.65m-86.33m224.24m34.00--0.9909--84.56-2.19-2.190.06725.670.0097----78,000.00-31.70---32.98-------3,255.17------0.00--382.80---255.21------
Celcuity Inc0.00-40.37m224.59m45.00--1.68-----2.61-2.610.006.170.00----0.00-30.86-37.87-32.01-39.28-----------40.240.2073-------36.36---7.92--
Fennec Pharmaceuticals Inc0.00-21.28m224.67m10.00--80.06-----0.8168-0.81680.000.10680.00----0.00-75.43-59.18-82.67-64.40-------38,331.77---32.690.8992---100.00--4.21------
OptiNose Inc76.28m-74.83m225.86m141.00------2.96-0.8805-0.88050.888-0.50790.49160.87022.20540,964.60-48.23-50.54-206.93-70.9987.8686.43-98.11-195.920.7332-3.191.79--2.18--9.07---51.74--
Gritstone bio Inc19.95m-119.69m227.04m233.00--1.32--11.38-1.38-1.380.23041.970.0769--19.4785,600.86-46.13-43.63-53.90-49.39-----600.09-590.74----0.1018---58.63---59.41---12.61--
Benson Hill Inc381.23m-99.70m227.55m440.00--1.17--0.5969-0.5497-0.70072.120.93820.73616.8212.04866,438.60-19.25---22.88--0.9252---26.15--2.58-5.830.354--319.19--18.41------
Savara Inc0.00-39.16m232.65m22.00--2.00-----0.2668-0.26680.001.020.00----0.00-23.38-40.84-24.54-43.63-------103,079.80---14.060.1825---100.00--13.30--48.10--
Rigel Pharmaceuticals Inc120.24m-58.57m232.70m155.00------1.94-0.3383-0.33830.7322-0.07850.79730.22234.31775,754.80-38.84-35.25-67.78-53.0898.5598.98-48.71-50.551.64-17.941.53---19.4393.05-226.97--22.37--
Actinium Pharmaceuticals Inc1.05m-30.38m233.17m32.00--3.24--221.44-1.30-1.300.04522.830.0105----32,906.25-30.18-73.21-32.19-87.46-----2,885.09-10,414.62----0.00007-------11.51--17.27--
Data as of Mar 30 2023. Currency figures normalised to Celcuity Inc's reporting currency: US Dollar USD

Institutional shareholders

36.82%Per cent of shares held by top holders
HolderShares% Held
RA Capital Management LPas of 31 Dec 20221.40m6.46%
Commodore Capital LPas of 31 Dec 20221.33m6.13%
Soleus Capital Management LP (Investment Management)as of 31 Dec 20221.21m5.59%
Morgan Stanley & Co. LLCas of 31 Dec 20221.02m4.72%
Frontier Wealth Management LLCas of 30 Jun 2022731.80k3.38%
PFM Health Sciences LPas of 31 Dec 2022712.11k3.29%
CapFinancial Partners LLCas of 31 Dec 2022630.91k2.91%
Millennium Management LLCas of 31 Dec 2022440.48k2.03%
The Vanguard Group, Inc.as of 31 Dec 2022426.83k1.97%
Jacob Asset Management of New York LLCas of 31 Dec 202273.21k0.34%
More ▼
Data from 30 Jun 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.